Antenatal Corticosteroids for Late-Preterm Infants: A Decision-Analytic and Economic Analysis

Table 3

Utility and cost estimates of neonatal health states.

Variable	Point estimate; (range)	Reference
Acute respiratory disease
Utility	0.87 (0.79–0.93)	[17]
Cost ($)
34 weeks	2,505 (334–50,657)
35 weeks	1,081 (315–31,866)	[18]
36 weeks	863 (305–18,370)
Chronic respiratory disease
Utility	0.88 (0.80–0.94)	[17]
Cost ($)	56,641 (5,919–74,217)	[19]
Neurodevelopmental; delay in childhood
Utility	0.76 (0.66–0.84)	[17]
Cost ($)	270,790 (135,395–541,582)	[20]
Death in childhood
Utility	0.01 (0.001–0.02)	[21]
Cost ($)	56,500 (27,960–83,881)	[22]
Child health
Utility	1.00 (1.00)	[17]
Cost ($)	0.00 (0.00)
Delivery cost
Without ACS ($)	8,449 (5452–13,980)	[22]
With ACS ($)	16,277 (11,414–17,628)	[23]

ACS: antenatal corticosteroids.